Acurx Advances Ibezapolstat Toward Phase 3 Development
Staten Island, New York, August 17, 2026 Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing antibiotics for difficult-to-treat bacterial...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Staten Island, New York, August 17, 2026 Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing antibiotics for difficult-to-treat bacterial...
STATEN ISLAND, N.Y., August 14, 2026 Acurx Pharmaceuticals, Inc. reported its second-quarter 2026 financial results and provided a business...
Toronto, Ontario, Canada, USA 10, 2026 Creyos has announced initial results from its implementation of digital cognitive testing across...
Johns Creek, Georgia, August, USA 10, 2026 Boehringer Ingelheim Animal Health is highlighting the next generation of veterinary researchers...
NEW YORK, May 6, 2026 Kingdom, a biotechnology company focused on clinically validated pet wellness ingredients, announced the publication...
CAMBRIDGE, Mass., April 9, 2026 Vedanta Biosciences, a late clinical-stage biopharmaceutical company, has announced new scientific presentations showcasing its...
Lyon, France, January 20, 2026 — MaaT Pharma, a late-stage clinical biotechnology company developing microbiome-driven immunotherapies, announced that the...
